Carprieve 50 mg Tablets for Dogs

Country: Ireland

Bahasa: Inggeris

Sumber: HPRA (Health Products Regulatory Authority)

Bahan aktif:

Carprofen

Boleh didapati daripada:

Norbrook Laboratories (Ireland) Limited

Kod ATC:

QM01AE91

INN (Nama Antarabangsa):

Carprofen

Dos:

50 mg/tablet

Borang farmaseutikal:

Tablet

Jenis preskripsi:

POM: Prescription Only Medicine as defined in relevant national legislation

Kawasan terapeutik:

carprofen

Status kebenaran:

Authorised

Tarikh kebenaran:

2003-07-25

Ciri produk

Health Products Regulatory Authority
25 June 2019
CRN0094PM
Page 1 of 4
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Carprieve 50 mg Tablets for Dogs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
Each tablet contains:
_ACTIVE SUBSTANCE:_
Carprofen 50 mg
_EXCIPIENTS:_
For a full list of excipients, see section 6.1
3 PHARMACEUTICAL FORM
Tablets:
A white/off white circular tablet with a break line on one face and 50
scored on the opposing face. The tablets can be divided
into equal halves.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Dogs
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For analgesia and reduction of chronic inflammation in musculoskeletal
disturbances in dogs, for example in degenerative joint
disease.
4.3 CONTRAINDICATIONS
Use of this product in cats is contra-indicated.Do not use in dogs
suffering from cardiac, hepatic or renal disease, where there
is a possibility of gastrointestinal ulceration or bleeding, or where
there is evidence of a blood dyscrasia or hypersensitivity to
the product.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
Refer to statements under Sections 4.3 and 4.5
4.5 SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS FOR USE IN ANIMALS: Use in dogs less than 6 weeks
of age, or in aged animals, may involve additional risk.
If such use cannot be avoided, such dogs may require a reduced dosage
and careful clinical management.
Avoid use in any dehydrated, hypovolaemic or hypotensive dog, as there
is a potential risk of increased renal toxicity.
NSAIDs can cause inhibition of phagocytosis and hence in the treatment
of inflammatory conditions associated with
bacterial infection, appropriate concurrent antimicrobial therapy
should be instigated.
SPECIAL PRECAUTIONS TO BE TAKEN BY THE PERSON ADMINISTERING THE
VETERINARY MEDICINAL PRODUCT TO ANIMALS:
None.
Health Products Regulatory Authority
25 June 2019
CRN0094PM
Page 2 of 4
4.6 ADVERSE REACTIONS (FREQUENCY AND SERIOUSNESS)
Typical undesirable effects associated with NSAIDs, such as vomiting,
soft faeces/d